Dr. Maisch HPLC Group Signs Agreement to Acquire a U.S.-based Chromatography Business, Including the Whelk-O® Portfolio

Acquisition to expand Dr. Maisch HPLC’s chiral and SFC capabilities and establish its first dedicated U.S. manufacturing presence

Ammerbuch, Germany / Morton Grove, Illinois — October 1, 2026

Dr. Maisch HPLC GmbH, a German manufacturer of high-performance liquid chromatography (HPLC) columns and stationary phases, today announced that it has entered into an agreement to acquire the Chromatography Business of Esteve CDMO US, Inc. (formerly known as Regis Technologies, Inc.). The transaction is expected to close in October 2026, subject to customary closing conditions.

The business to be acquired includes the internationally established Whelk-O® chiral HPLC and SFC platform, achiral SFC and reversed-phase columns, Immobilized Artificial Membrane (IAM) chromatography products, specialty ion-pairing and derivatizing reagents, as well as chiral screening services.

Financial and other terms of the transaction were not disclosed.

The acquisition brings together two highly complementary chromatography portfolios. The acquired Chromatography Business contributes decades of expertise in chiral separations, SFC, IAM chromatography and specialty reagents, while Dr. Maisch HPLC adds its broad capabilities in stationary-phase development, analytical and preparative HPLC columns, and customized chromatography solutions.

Following closing, the U.S. chromatography business will operate from the Chicago area under the name Regis ChroMa Inc., a Dr. Maisch company. The transaction will establish Dr. Maisch HPLC’s first dedicated manufacturing and commercial operation in the United States, giving the company a dedicated U.S. base and supporting its long-term growth in the U.S. market.

The announcement comes ahead of SFC Europe 2026, taking place October 4–6, 2026 in Basel, Switzerland, an international meeting focused on technologies and applications in supercritical fluid chromatography.

“The acquired Chromatography Business has built an outstanding reputation in separation science over many decades, and Whelk-O® has become a widely recognized name in chiral chromatography. Bringing that expertise together with our HPLC technology and manufacturing strengths creates a highly complementary platform across chiral and achiral separations,” said Dr. Johannes Maisch, CEO of Dr. Maisch HPLC GmbH.

“Establishing our own operation in the United States is an important step in the long-term development of Dr. Maisch HPLC, and we intend to build a strong presence there,” Maisch added. “Customers can expect continuity in the products and expertise they know from the acquired Chromatography Business, with the same focus on quality — now supported by the broader manufacturing capabilities of Dr. Maisch HPLC.”

About Dr. Maisch HPLC

Dr. Maisch HPLC GmbH, headquartered in Ammerbuch, Germany, develops and manufactures high-performance liquid chromatography columns, stationary phases and customized chromatography solutions for pharmaceutical, biotechnology and analytical laboratories worldwide.

Founded in 1996, the company has three decades of experience in chromatography and serves applications ranging from analytical method development to preparative purification. Its portfolio includes the ReproSil-Pur, ReproShell, MODcol and NanoFusion product families as well as a broad range of analytical, preparative and custom column formats.

About the acquired Chromatography Business

The acquired Chromatography Business traces its roots to 1966 and has developed a long-standing reputation in separation science. Its portfolio includes the Whelk-O® chiral separation platform, achiral SFC and reversed-phase columns, Immobilized Artificial Membrane (IAM) chromatography products, specialty chromatography reagents and chiral screening capabilities.

Following completion of the transaction, the acquired chromatography business will operate under Regis ChroMa Inc. in the Chicago area as part of Dr. Maisch HPLC.